肝癌组织乙酰肝素酶的表达及其与微血管密度的关系

doi:10.3969/j.issn.1672-5069.2015.06.019

摘要/Abstract

摘要： 目的观察乙酰肝素酶（Hpa）在肝癌组织中的表达,并探讨其与微血管密度（MVD）的关系。方法采用RT-PCR法检测47例原发性肝癌组织、癌旁组织1（A组）和癌旁组织2（B组）Hpa mRNA水平;采用免疫组织化学法检测肝癌组织Hpa蛋白和CD34表达水平,并分析Hpa蛋白与肝癌临床病理特征的关系,以及Hpa mRNA水平与MVD值的相关性。结果在不同直径和分化程度、不同临床分期、是否转移复发、AFP水平和有无门脉癌栓等肿瘤组织,Hpa蛋白表达存在明显的差异（P<0.05）;肝癌组织Hpa mRNA水平（0.793±0.184）和MVD值（34.5±12.2）均明显高于A组和B组（P<0.05）,而A组Hpa mRNA水平（0.577±0.145）和MVD值（22.2±10.7）又明显高于B组[（0.384±0.117）和（14.7±7.4）,P<0.05];各组Hpa mRNA水平与MVD值呈正相关（r=0.627,P<0.05）。结论Hpa在肝癌的生长、侵袭和血管生成中发挥着重要作用。

关键词: 肝癌, 乙酰肝素酶, 微血管密度

Abstract: Objective To explore the expression of heparanase（Hpa） in liver cancer tissues, and its relationship with the microvascular density（MVD）. Methods The Hpa mRNA levels in tumor, close-adjacent cancerous （group A） and peri-cancerous liver tissues （group B） from 47 patients with primary liver cancer were detected by RT-PCR. The expression of Hpa protein and CD34 in liver and cancer tissues were detected by immunohistochemistry. The correlation of Hpa mRNA to MVD in tissues with different clinical and pathological characteristics were analyzed. Results There were significant differences between Hpa levels in tumor tissues with different differentiation and clinical stages,with or without metastasis and recurrence,high or low AFP levels,with or without portal vein tumor emboli,and large or small tumor sizes （P<0.05）;The Hpa mRNA levels （0.793±0.184） and the MVD（34.5±12.2） in liver cancerous tissues were significantly higher than those in group A and group B （P<0.05）,while the Hpa mRNA levels and MVD in group A were significantly higher than those in group B [（0.577±0.145） vs. （0.384±0.117）,and （22.2±10.7） vs. （14.7±7.4）,respectively,P<0.05];The Hpa mRNA level in each group was positively correlated with MVD（r=0.627,P<0.05）. Conclusion Hpa plays an important role in the growth,invasion and angiogenesis of hepatocellular carcinoma.

Key words: Hepatocellular carcinoma, Heparanase, Microvascular density

杨其容，张平安. 肝癌组织乙酰肝素酶的表达及其与微血管密度的关系[J]. 实用肝脏病杂志, 2015, 18(6): 643-646.

Yang Qirong， Zhang Ping'an.. Expression of heparanase in liver cancer tissues and its relationship with microvascular density[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 643-646.

参考文献

[1] 杨浩,杨连粤. 肝癌术后复发转移相关因素研究进展. 中国实用外科杂志,2012,32（10）:868-870.
[2] 邱谢武,于聪慧. 肝癌干细胞与肝癌复发转移的研究进展.世界华人消化杂志,2011,19（17）:1802-1807.
[3] Nadir Y,Brenner B. Heparanase multiple effects in cancer.Thrombosis Res,2014,133（Suppl 2）:S90-S94.
[4] 石志良,秦锡虎,朱峰,等. 肝细胞肝癌中乙酰肝素酶mRNA的表达及其意义. 实用临床医学,2006,7（8）:1-3.
[5] Seifert C,Wittig S,Arndt C,et al. Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation. J Cancer Res Clin,2015,141（5）:877-885.
[6] Roucourt B,Meeussen S,Bao J,et al. Heparanase activates the syndecan-syntenin-ALIX exosome pathway.Cell Res,2015,25（4）:412-428.
[7] Zeng C,Chen L,Yang Z,et al. The close correlation between heparanase and COX-2 expression in lymphangiogenesis of cervical cancer. Med Oncol,2014,31（12）:314.
[8] Gawthorpe S,Brown JE,Arif M,et al. Heparanaseand COX-2 expression as predictors of lymph node metastasis in large,high-grade breast tumors. Anticancer Res,2014,34（6）:2797-2800.
[9] Pisano C,Vlodavsky I,Ilan N,et al. The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol,2014,89（1）:12-19.
[10] Masola V,Secchi MF,Gambaro G,et al. Heparanase as a target in cancer therapy. Curr Cancer Drug Targets,2014,14（3）:286-293.
[11] Novick D,Barak S,Ilan N,et al. Heparanase interacts with resistin and augments its activity.PloS one,2014,9（1）:e85944.
[12] Meirovitz A,Goldberg R,Binder A,et al. Heparanase in inflammation and inflammation-associated cancer. The FEBS J,2013,280（10）:2307-2319.
[13] Cohen E,Doweck I,Naroditsky I,et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer,2008,113（5）:1004-1012.
[14] 田志宏,王顺祥,张凤瑞. 乙酰肝素酶在原发性肝细胞肝癌中的表达及临床意义. 河北医科大学学报,2007,28（3）:172-174.
[15] 崔京远,马红,马文慧,等. 结肠癌组织中Cyr61和HPA-1的表达水平及其在侵袭转移中的作用.中国现代普通外科进展,2012,15（6）:439-443.
[16] 刘华敏,李玉军,梁军,等. 胰腺癌组织乙酰肝素酶表达及其与肿瘤血管形成及预后关系的研究.中华肿瘤防治杂志,2008,15（2）:134-137.
[17] 朱陈辉,胡卫列,夏照明,等. 环氧合酶-2和乙酰肝素酶-1在肾上腺皮质肿瘤中的表达及临床意义.实用医学杂志,2012,28（9）: 1465-1468.
[18] 乔建霞,师水生. Delta like蛋白及乙酰肝素酶在食管鳞状细胞癌中的表达及其与微血管密度关系的研究.中国药物与临床,2012,12（8）:1020-1023.
[19] 王贺,孙风波,邢智远,等. 原发性肝癌组织中LASP-1 mRNA和HPA-1 mRNA表达水平及其临床意义.中国临床研究,2014,27（6）:641-643.
[20] 肖影群,邓茜,梁青,等. 早期肝细胞肝癌组织中乙酰肝素酶、b-FGF、CD34的表达与微血管密度的关系及其病理和临床意义.南昌大学学报（医学版）,2010,50（4）:4-9.
[21] 温德才,高若辉,李秀军. 胆囊癌组织乙酰肝素酶的表达与胆囊癌临床病理参数及微血管密度的关系.江苏医药,2011,37（19）:2302-2304.